Madhi, S.A., Moodley, D., Hanley, S., Archary, M., Hoosain, Z., Lalloo, U., Louw, C., Fairlie, L., Fouche, L.F., Masilela, M.S. and Singh, N., 2022. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. The Lancet HIV, 9(5), pp.e309-e322.
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
- Journal Articles
